Billing and Coding: MolDX: Abbott RealTime IDH1 and IDH2 testing for Acute Myeloid Leukemia (AML)

Abbott RealTime IDH1 and IDH2 tests (Abbott Molecular) are covered for adult patients (age >=18) with relapsed or refractory AML to identify IDH1 or IDH2 mutations for determining eligibility for targeted therapies (ivosidenib or enasidenib). Coverage applies to FDA-approved, unmodified Abbott kits; modified tests or non–FDA-approved uses require submission of a MolDX Technical Assessment and MolDX determination prior to claims. Claims must use CPT 81120 (IDH1) or 81121 (IDH2), report 1 unit of service, include appropriate ICD-10-CM diagnosis coding, and include the DEX Z-Code in the specified claim fields.

"Abbott RealTime IDH1 (Abbott Molecular) is covered for adult patients (age >=18) with relapsed or refractory acute myeloid leukemia (AML) to identify an IDH1 mutation for determining eligibility fo..."

Sign up to see full coverage criteria, indications, and limitations.